Results of AGM
London, 10th June 2020
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that at its Annual General Meeting held on Tuesday, 9th June 2020, all resolutions set out in the notice of meeting were duly passed on a poll.
The votes were as follows:
|
Resolution |
Votes for |
% |
Votes against |
% |
Votes total |
% of ISC voted |
Votes withheld |
|
1 - Report and accounts |
51,506,649 |
99.4 |
302,395 |
0.6 |
51,809,044 |
62.6% |
13,621 |
|
2 - Re-appoint Steven Romano |
51,463,539 |
99.3 |
359,013 |
0.7 |
51,822,552 |
62.6% |
113 |
|
3 - Re-appoint auditor and auditor remuneration |
51,659,333 |
99.7 |
163,219 |
0.3 |
51,822,552 |
62.6% |
113 |
|
4 - Allot shares |
47,496,295 |
99.9 |
49,677 |
0.1 |
47,545,972 |
57.4% |
4,276,693 |
|
5 - Disapply pre-emption rights |
46,863,893 |
98.6 |
682,079 |
1.4 |
47,545,972 |
57.4% |
4,276,693 |
The number of the Company's ordinary shares in issue as at the date of the meeting was 82,796,259 ordinary shares of 5p each.
A vote withheld is not a vote in law and has not been counted in the calculation of the proportion of votes for and against the resolutions.
Dr. Giles Campion who, as a result of being appointed to the Board after the notice of Annual General Meeting was posted to shareholders, vacated his office as a director at the conclusion of the Annual General Meeting and was re-appointed as a director by the Board immediately thereafter in accordance with the Company's articles of association. Dr Campion will stand for re-election at the next annual general meeting of the Company in 2021.
Enquiries:
|
Silence Therapeutics plc Iain Ross, Executive Chairman Dr Rob Quinn, Chief Financial Officer
|
Tel: +44 (0)20 3457 6900 |
|
Investec Bank plc (Nominated Adviser and Broker) Daniel Adams/Gary Clarence
|
Tel: +44 (0) 20 7597 5970 |
|
European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray silencetherapeutics@consilium-comms.com
|
Tel: +44 (0) 20 3709 5700 |
|
US IR Westwicke Partners Peter Vozzo peter.vozzo@westwicke.com
|
Tel: +1 (443) 213-0505 |
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
